Navigation Links
Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
Date:2/10/2011

curities during 2010 and a one-time $1.4 million loss recognized on auction rate securities in 2009.

2011 Financial GuidanceThe Company expects to have a net cash burn from operations of approximately $3 to $6 million in 2011. Revenue is expected to increase to approximately $75 to $80 million which includes amortization of up-front license fees of approximately $36 million and anticipated milestones earned under collaboration agreements of approximately $30 million. Expenses for 2011 should approximate $44 to $48 million. Net income for 2011 is expected to be $34 to $39 million, or $0.62 to $0.71 cents per share based on 55 million basic shares outstanding. The Company expects to end 2011 with approximately $130 million in cash, investments and receivables.

Pipeline HighlightsElagolix UpdateAbbott and Neurocrine requested an end of Phase II meeting last year and the companies are scheduled to meet with the FDA in March 2011. The Companies are currently preparing the briefing document for the FDA meeting. This document will encompass the entirety of the elagolix endometriosis program thus far including, twelve Phase I studies and six Phase II studies in over 1,000 subjects for up to six months of continuous treatment. Upon receipt of the written minutes of the March 2011 meeting, the Company will provide an update as to the timing around the elagolix clinical program.

Urocortin 2 UpdateThe Christchurch Cardioendocrine Research Group at University of Otago, Christchurch School of Medicine and Health Sciences, New Zealand, in collaboration with the Company, is enrolling patients with Acute Decompensated Heart Failure in a Phase II study of urocortin 2, and has enrolled 39 patients as of mid-January, of a planned total patient population of 50.

Additionally, urocortin 2 studies are underway at the Centre for Cardiovascular Sciences at The University of Edinburgh through a British Heart Foundation grant. Nine studies are expec
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
2. Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
3. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
4. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
5. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
6. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
7. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
8. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
9. Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain
10. Neurocrine Biosciences Amends Corporate Headquarters Lease
11. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... Sterne, Kessler, Goldstein & Fox P.L.L.C. , an intellectual ... , announced today that it has filed eleven petitions ... U.S. Patent and Trademark Office (USPTO) on behalf of ... BRLI).  These IPR petitions aim to nullify eleven patents ... patents have been asserted against GeneDx in patent infringement ...
(Date:8/18/2014)... Global HIV Infection Drug Market and Pipeline Insight ... rate of HIV infection and the number of deaths due ... positive rate across the globe. It has been estimated that ... 1.5 in 2013, with the rates for children being even ... the infection rates has been the improved access to antiretroviral ...
(Date:8/18/2014)... , August 18, 2014 ... Bioreactor Systems Market, By Application (Municipal Wastewater Treatment ... Flat Sheet and Multi Tubular), By Configuration (Internal/Submerged ... 2019", published by MarketsandMarkets, The market for membrane ... by 2019, growing at a CAGR of 15.28% ...
(Date:8/18/2014)... 2014 Dyadic International, Inc. ("Dyadic") (OTCQX: ... proprietary technologies are used to develop, manufacture and ... bio-based chemical, biopharmaceutical and industrial enzyme industries, announced ... on Form 10 with the U.S. Securities and ... http://photos.prnewswire.com/prnh/20110621/CL06708LOGO The Form ...
Breaking Biology Technology:Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3Dyadic International Files Form 10 Registration Statement 2Dyadic International Files Form 10 Registration Statement 3Dyadic International Files Form 10 Registration Statement 4
... from the nations nuclear weapons program lie in a ... Beneath this desert landscape about two million curies of ... are captured within the stratified vadose zone below which ... paths create uncertainties about where the contaminants go and ...
... - Researchers have developed a new modeling technique ... that could help industry perfect lab-on-a-chip technology for ... , The experimental devices represent a new class ... specific "target molecules," which will allow the sensors ...
... PAUL, Minn., Jan. 3 /Xinhua-PRNewswire/ --,WuXi PharmaTech ... of pharmaceutical R&D,outsourcing services, has signed a ... Inc. (AppTec). The acquisition of AppTec allows,WuXi ... expertise,gain a significant U.S. operational footprint, and ...
Cached Biology Technology:Where does stored nuclear waste go? 2Model is first to compare performance of 'biosensors' 2Model is first to compare performance of 'biosensors' 3WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc. 2WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc. 3WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc. 4WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc. 5
(Date:8/20/2014)... Washington , August 20, 2014 ... Concerns in the Payment Industry?   Investorideas.com ... including biometrics, issues commentary from analysts and experts on the ... Managing Partner at Thrive Analytics, Isabelle Moeller of ... NXT-ID, Inc. (OTCBB: NXTD) ( OTCQB:NXTD ), a biometric company ...
(Date:8/19/2014)... systems be used in supermarkets to encourage healthier spending ... to answer that very question by tracking the purchasing ... Stars System to rate the nutritional value of foods ... Brand Lab,s David Just, PhD, and Brian Wansink PhD, ... records of over 150 Hannaford Supermarkets in the Northeastern ...
(Date:8/19/2014)... parts of the world, leprosy and tuberculosis live ... of leprosy per year, with nearly all of ... available century-old vaccine Bacille Calmette-Guerin, or BCG, provides ... so a more potent vaccine is needed to ... a stronger weapon against both diseases., In a ...
Breaking Biology News(10 mins):Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 3Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 4Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 5Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 6Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 7New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2
... 3 HIV vaccine efficacy trial are reported in the March ... online. Although the vaccine was ineffective in preventing HIV infection, ... and offers the scientific community a foundation on which to ... United States and the Netherlands and completed in 2003, is ...
... evidence in laboratory studies that the immune system may ... the drug through an unusual vaccine-like mechanism. Their finding, ... chronic users go on long binges with the illicit ... to new treatments for the drug's addiction, they say. ...
... access publishing and the NIH new policy from ... of Health (NIH) rule on Enhanced Public Access to ... and a missed opportunity to take advantage of available ... the nation's leading not-for-profit medical and scientific publishers. The ...
Cached Biology News:HIV vaccine trial breaks ground for future research 2Chemists identify immune system mechanism for methamphetamine binges 2Chemists identify immune system mechanism for methamphetamine binges 3Not-for-profit publishers call NIH public access rule a missed opportunity 2Not-for-profit publishers call NIH public access rule a missed opportunity 3
... Tracker Intracellular Localization Kit provides a straight ... siRNA, of your design, in an efficient ... experiments. Subcellular localization and functional inhibition of ... introduction of the labeled siRNA into mammalian ...
Ideal for chemical processing that requires downward flow of exhaust fumes. Powderful 1200 CFM blower draws fumes into sub-surface bonded charcoal filter for safe removal of organic vapors (final HEP...
... siRNA Tracker Intracellular Localization Kit with ... forward approach to directly label and ... an efficient yet non-destructive manner, for ... and functional inhibition of target gene ...
... IT siRNA Tracker Intracellular Localization Kit provides ... and deliver siRNA, of your design, in ... vitro tracking experiments. Subcellular localization and functional ... monitored following introduction of the labeled siRNA ...
Biology Products: